Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
acalabrutinib
adverse events
Bruton tyrosine kinase inhibitor
chronic lymphocytic leukemia
ibrutinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55

Ejemplares similares